KDM5A: A Potential Drug Target for Cancer (G5927)

Target Name: KDM5A

NCBI ID: G5927

KDM5A

KDM5A: A Potential Drug Target for Cancer

KDM5A, also known as KDM5A_HUMAN, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. The gene is located on chromosome 16 and encodes a protein known as NEDD8-activating enzyme 5A (NAD+-dependent DNA polymerase 5A).

NAD+ is a crucial coenzyme found in all living cells that plays a vital role in various cellular processes, including energy metabolism, DNA replication, and signaling pathways. The NAD+-dependent DNA polymerase 5A is a key enzyme that modifies the nucleotide base adenine (A) to form adenosine (A), which has been linked to various health conditions, including cancer.

KDM5A has been shown to promote the growth and survival of cancer cells, and high levels of expression of the gene have been observed in various types of cancer, including breast, ovarian, and prostate cancers. Additionally, the gene has also been associated with various other diseases, including cardiovascular disease, neurodegenerative diseases, and autoimmune disorders.

Due to its potential as a drug target, KDM5A has been the focus of research in recent years, and various studies have been conducted to investigate its role in cancer progression and treatment. One study published in the journal Nature Medicine used RNA sequencing to identify KDM5A as a promising target for cancer treatment. The study found that the gene was expressed in various types of cancer and that inhibiting its activity could be an effective way to treat these diseases.

Another study published in the journal Oncogene used a similar approach to investigate the role of KDM5A in cancer progression. The study found that overexpression of the gene was associated with cancer cell migration and invasion, and that inhibiting its activity could be an effective way to treat cancer.

While more research is needed, the potential of KDM5A as a drug target is exciting. If its role in cancer progression can be confirmed, it could be used to develop new treatments for a variety of diseases. Additionally, the gene could also be used as a biomarker to predict disease outcomes, such as the effectiveness of cancer treatments.

In conclusion, KDM5A is a gene that has shown promising potential as a drug target or biomarker for a variety of diseases, including cancer. Further research is needed to confirm its role and develop effective treatments.

Protein Name: Lysine Demethylase 5A

Functions: Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Regulates specific gene transcription through DNA-binding on 5'-CCGCCC-3' motif (PubMed:18270511). May stimulate transcription mediated by nuclear receptors. Involved in transcriptional regulation of Hox proteins during cell differentiation (PubMed:19430464). May participate in transcriptional repression of cytokines such as CXCL12. Plays a role in the regulation of the circadian rhythm and in maintaining the normal periodicity of the circadian clock. In a histone demethylase-independent manner, acts as a coactivator of the CLOCK-BMAL1-mediated transcriptional activation of PER1/2 and other clock-controlled genes and increases histone acetylation at PER1/2 promoters by inhibiting the activity of HDAC1 (By similarity). Seems to act as a transcriptional corepressor for some genes such as MT1F and to favor the proliferation of cancer cells (PubMed:27427228)

The "KDM5A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDM5A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets